NOMAD POWER SOLUTIONS, INC. Contract Liability (Deferred Revenue)
NOMAD POWER SOLUTIONS, INC. (NMAD) had Contract Liability (Deferred Revenue) of $15.77 thousand as of 2020-12-31, per its 10-K filed 2021-03-26.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2021-03-26
- 2020-12-31: Contract with Customer, Liability, Current $15.77K.
- 2019-12-31: Contract with Customer, Liability, Current $94.35K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2020-12-31 | $15.77K 10-K · filed 2021-03-26 |
| 2019-12-31 | $94.35K 10-K · filed 2021-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B |